Business
Ventripoint Issues Shares for Debt Settlement and Awards Option Grants
(TheNewswire)   Toronto, Ontario – TheNewswire - January 28, 2026 – ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Issues Shares for Debt Settlement and Awards Option Grants\n(TheNewswire)\n\n\n\n \n\n\nToronto, Ontario – TheNewswire - January 28, 2026 –\nVentripoint Diagnostics Ltd. (\"Ventripoint\" or\nthe \"Corporation\", TSXV:VPT) is pleased to announce that it received approval from the TSX Venture Exchange\n(“TSXV”) and has issued 4,276,964 common shares (the “Shares”) of the\nCorporation to settle an aggregate of\n$427,696.35 of debt owed to certain arm’s length creditors of the\nCorporation at a price of $0.10 per share. \n\n\n \n\n\nThe Shares are subject to a hold period of four months\nand one day. The Corporation determined to satisfy the indebtedness\nwith Shares in order to preserve its cash for development of its\nbusiness. \n\n\n \n\n\nThe Company has also issued option grants on January 20, 2026, the Corporation granted an aggregate of\n2,516,500 options to directors, officers, employees, contractors and\nconsultants of the Corporation with an exercise price of $0.12 and\nterms of between 2 (two) to 10 (ten) years, vesting from immediately\nto over a 3 (three) year period. Of these option grants, 200,000 were\nawarded to directors and an additional 1,300,000 were awarded to\nofficers some of which are also directors of the Corporation.\n \n\n\n \n\n\nThese annual option grants are an important part of\nincentivizing stakeholders to drive value in the Corporation.\n\n\n \n\n\nSince the last update (see NR June 17, 2025), a\ntotal of 780,000 options were exercised with a weighted average price\nof approximately $0.105 per share for gross proceeds to the\nCorporation of $81,800.00.  There are currently 16,683,500 option grants outstanding\nwith exercise prices between $0.10 to $0.50 with a weighted average\nprice of $0.17, and 14,555,167 of these option grants have vested.\n\n\n \n\n\nThe Corporation has approximately 2.0 million options available for future grants under the Stock Option\nPlan as approved by shareholders at the last Special and Annual\nGeneral Meeting of the Corporation.\n\n\n \n\n\nAbout Ventripoint Diagnostics\nLtd.\n\n\n \n\n\nVentripoint has become an\nindustry leader in the application of AI (Artificial Intelligence) to\nechocardiography. Ventripoint's VMS products are powered by its\nproprie...